Why the study?
Is asleep blood pressure derived from 48-h ABPM a more significant prognostic marker for cardiovascular events compared to office or awake blood pressure?
Is asleep blood pressure derived from 48-h ABPM a more significant prognostic marker for cardiovascular events compared to office or awake blood pressure?
Answers are grounded in this paper and cite their sources.
This editorial highlights evidence that asleep systolic blood pressure is a superior prognostic marker for cardiovascular events compared to office blood pressure, suggesting it as a potential target for antihypertensive therapy.
This editorial refers to ‘Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention’†, by R.C. Hermida et al., on page 4159. The use of out-of-office blood pressure (BP) monitoring, including ambulatory BP monitoring (ABPM), is increasingly encouraged in clinical practice. The 2018 ESC/ESH Hypertension Guidelines highlight the added value of 24-h BP monitoring and provide some clinical indications for its use, though still considering office BP as the reference measure for diagnosis and treatment efficacy assessment,1 while other guidelines, such as those from the National Institute for Health and Clinical Excellence in the UK, recommend ABPM for confirming each diagnosis of hypertension. A number of studies have shown that in hypertensive patients, ambulatory BP correlated more closely to organ damage and to cardiovascular morbidity and mortality than office BP, possibly because of the ability of 24-h systolic and diastolic BP to better depict the haemodynamic load magnitude associated with hypertension.2 Furthermore, the use of ABPM allows detection of different BP patterns, including masked, systolic, and isolated clinical hypertension, which might convey a different cardiovascular risk.3 Among the main advantages of the extensive use of ABPM, there is the possibility of evaluating the circadian profile of BP, and thus to derive time-dependent components (namely daytime and night-time BP) and circadian BP variability patterns (such as dipping status, night-to-day BP ratio, morning surge, short-term BP variability, and so on). A lot of effort has been put into understanding the prognostic impact of ABPM-derived variables. Interestingly, in the last years, evidence is accumulating about the superiority of night-time BP, for its greater prognostic value and its better reproducibility in comparison with other ABPM-derived variables. A meta-analysis of prospective studies4 concluded that night-time BP was a stronger predictor of cardiovascular events and total mortality even after additional adjustment for daytime BP, while night-to-day BP ratio and dipping status provide only modest, if any, additional prognostic value over and beyond the 24-h BP mean values. Many mechanisms have been hypothesized to explain the increased cardiovascular risk associated with elevated night-time BP (Take home figure), including alterations in the sympathetic BP modulation and/or in baroreflex sensitivity, obstructive sleep apnoea syndrome and other sleep disorders, increased salt sensitivity, leptin and insulin resistance, and endothelial dysfunction.5 Furthermore, night-time BP is by definition acquired in more standardized conditions than the daytime BP, in terms of physical and mental activity as well as body position. Indeed, daytime BP may be increased in highly physically active individuals, who are instead at a lower cardiovascular risk. Possible mechanisms explaining the greater prognostic value of asleep blood pressure (BP). In the present issue of the European Heart Journal, the results of the Hygia Project are published,6 providing further evidence of the clinical relevance of night-time BP. The Hygia Project is a prospective, multicentre, primary care-based study: for the present analysis, ∼15 674 individuals (9709 untreated for hypertension), referred for ABPM to confirm the diagnosis of hypertension in untreated individuals or to evaluate BP control in treated hypertensive patients, were enrolled. They underwent repeated 48-h ABPM and were followed up for a median duration of 5.1 years, during which 1209 cardiovascular events occurred. The first main result of the study is that asleep systolic BP at baseline was the most significant ABPM-derived variable associated with cardiovascular events, in a model adjusted, among others, for office and awake systolic BP. Two important methodological aspects should be taken into account. First, the monitoring duration was 48 h, instead of the most usual 24 h, in order to guarantee a greater consistency of the results. Indeed, reproducibility of ABPM-derived variables is known to be suboptimal, though greater for absolute night-time BP values.7 An increased BP duration may increase reproducibility of these variables, though at the expense of a possibly lower compliance of the patient and a lesser availability of this kind of examination worldwide and in the clinical setting.8 Indeed, since the drop-out rate for such a demanding protocol appears to be extremely low, a selection bias could be hypothesized. Even after the cost-effectiveness of 24-h BP use in each new hypertension diagnosis has been demonstrated, strategies to cut ABPM use are welcome,9 especially in low-resource settings. In this context, the 48-h BP monitoring appears to be hardly applicable; thus a direct comparison with 24-h BP is warranted. Secondly, asleep and awake BP were computed according to the participants’ diary of daily activities, whereas long or short clock time intervals were also used.4 Current guidelines recommend short clock time intervals to define day (0900 to 2100 h) and night (0100 to 0600 h), based both on practical issues and on study results.2 A future analysis of the Hygia Project data set may provide a direct comparison between the prognostic values of different definitions of night-time/asleep BP. However, the most relevant results of the present study concern the prognostic value of treatment-induced asleep BP changes over time in repeated ABPM assessments. ABPM-derived asleep BP was the most relevant biomarker of cardiovascular risk among ABPM-derived variables, with a prognostic value over and above changes in office BP. ABPM is extensively used in clinical trials and prospective cohort studies, and its use is strongly recommended by current European Medicines Agency (EMA) guidelines for the evaluation of new antihypertensive agents, even if always accompanied by office BP. While the predictive value of baseline night-time BP has already been demonstrated,4 these promising results support the hypothesis that night-time BP may be considered a target for antihypertensive treatment. To confirm this hypothesis finally, however, some other steps are necessary. First, these results should be replicated by independent research groups in different cohorts, including different ethnicities. Secondly, it should be verified whether asleep BP changes, assessed by 24-h BP monitoring, retain the same prognostic value. Thirdly, multicentre randomized clinical trials are required to demonstrate the superiority (in terms of cardiovascular event reduction) of a therapeutic strategy based on asleep BP in comparison with one based on office or 24-h BP. In 1997, Staessen and co-authors demonstrated that a therapeutic strategy based on average 24 h diastolic BP is equally effective (but using fewer drugs) in controlling BP and avoiding left ventricular hypertrophy as a strategy based on office diastolic BP, but not superior in terms of cost-effectiveness.10 More evidence from this type of trial is needed before considering asleep BP a novel target for BP treatment.
No takes yet. Share an insight, caveat, or question.
Bruno et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: